Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacovigilance

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 Study.

Clinical breast cancer·2026

Same author

Non-antibiotic management of bacterial keratitis.

Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society·2026

Same author

Evidence and Consensus Based Guidelines for Imaging in Tubercular Choroiditis. Multimodal imaging in Uveitis (MUV) Taskforce: Report 17.

Ophthalmology. Retina·2026

Same author

Imaging Features of Herpetic Interstitial Keratitis by Anterior Segment Optical Coherence Tomography.

Cornea·2026

Same author

Emerging therapeutic targets in non-infectious uveitis and scleritis.

Frontiers in medicine·2026

Same author

Evidence and Consensus-Based Guidelines in Vogt-Koyanagi-Harada Disease. Multimodal Imaging in Uveitis (MUV) Taskforce Report 16.

Ophthalmology. Retina·2026

Search research articles

Related Experiment Video

Updated: Jan 6, 2026

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Published on: August 9, 2024

Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting.

Neel D Pasricha^1,2, Stella K Kim³, Asim V Farooq⁴

¹Department of Ophthalmology, University of California, San Francisco.

JAMA Ophthalmology

|December 4, 2025

Summary

New ocular grading scales improve the reporting of adverse events (AEs) in patients receiving experimental oncology drugs. These standardized scales enhance patient safety and guide the development of novel cancer therapies.

More Related Videos

Intravitreous Injection for Establishing Ocular Diseases Model

Intravitreous Injection for Establishing Ocular Diseases Model

Published on: October 1, 2007

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

Related Experiment Videos

Last Updated: Jan 6, 2026

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Published on: August 9, 2024

Intravitreous Injection for Establishing Ocular Diseases Model

Intravitreous Injection for Establishing Ocular Diseases Model

Published on: October 1, 2007

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

Area of Science:

Ophthalmology
Oncology
Clinical Trials

Background:

Current ocular Common Terminology Criteria for Adverse Events (CTCAE) lack standardization, mixing signs and symptoms, and omitting dose modification guidance.
Robust reporting of ocular adverse events (AEs) is crucial for patient safety and developing effective oncology drugs.

Purpose of the Study:

To develop improved ocular AE grading scales for evaluating AEs in patients undergoing experimental oncology drug therapy.
To provide clear drug dose modification recommendations for ocular AEs.

Main Methods:

A collaborative multicenter working group of oncologists and ophthalmologists was formed in February 2023.
Expert consensus was reached on novel experimental oncology drug-related ocular AE grading scales, which were released in June 2023.

Main Results:

Six novel ocular AE grading scales were developed for antibody-drug conjugate clinical trials: visual acuity, eye symptoms, cornea, conjunctiva/sclera, anterior chamber, and retina/posterior segment.
These scales incorporate standardized clinical photographs where applicable.

Conclusions:

The new scales are more concise than previous CTCAE and include clear drug dose modification recommendations.
These grading scales promote objective and consistent measurement of ocular AEs, aiding safe testing of novel oncology agents.